Amgen is acquiring biotechnology company Five Prime Therapeutics for $1.9 billion, or $38 per share. Five Prime Therapeutics developed bemarituzumab, a targeted immunotherapy for gastric cancer and other solid tumors, which has shown positive results in Phase II clinical trials. The deal is expected to close by the end of the second quarter of this year.
Amgen is acquiring biotechnology company Five Prime Therapeutics for $1.9 billion, or $38 per share. Five Prime Therapeutics developed bemarituzumab, a targeted immunotherapy for gastric cancer and other solid tumors, which has shown positive results in Phase II clinical trials. The deal is expected to close by the end of the second quarter of this year. 
investors.amgen.com
English (US) 